Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Anatara Lifesciences Ltd ( (AU:ANR) ) has issued an announcement.
Anatara Lifesciences has converted 2,360,426 ANRAR performance rights into an equivalent number of ordinary shares for an employee, following the satisfaction of vesting conditions and the employee’s election to receive the shares. The company issued a cleansing notice confirming the shares were issued without a prospectus, that it remains compliant with relevant Corporations Act reporting and disclosure obligations, and that there is no undisclosed price-sensitive information, signalling routine capital management with no hidden regulatory or informational risks for investors.
The most recent analyst rating on (AU:ANR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Anatara Lifesciences Ltd stock, see the AU:ANR Stock Forecast page.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is an ASX-listed company developing and commercialising innovative, evidence-based health products targeting areas of significant unmet medical need. The company is focused on building a pipeline of human health products, particularly for complex gastrointestinal conditions, with an emphasis on delivering tangible patient outcomes and shareholder value.
Average Trading Volume: 573,922
Technical Sentiment Signal: Sell
Current Market Cap: A$3.45M
See more insights into ANR stock on TipRanks’ Stock Analysis page.